Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update

References

• Passweg JR, Baldomero H, Chabannon C, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021. doi:10.1038/s41409-021-01227-8.
   Web of Science ®Google Scholar
• To LB, Dyson PG, Juttner CA. Cell-dose effect in circulating stem-cell autografting. Lancet. 1986;2(8503):404–405. doi:10.1016/s0140-6736(86)90096-6.
   PubMed Web of Science ®Google Scholar
• Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood. 1995;86(10):3961–3969. doi:10.1182/blood.V86.10.3961.bloodjournal86103961
   PubMed Web of Science ®Google Scholar
• Namdaroglu S, Korkmaz S, Altuntas F. Management of mobilization failure in 2017. Transfus Apher Sci. 2017;56(6):836–844. doi:10.1016/j.transci.2017.11.017.
   Web of Science ®Google Scholar
• Armitage S, Hargreaves R, Samson D, Brennan M, Kanfer E, Navarrete C. CD34 counts to predict the adequate collection of peripheral blood progenitor cells. Bone Marrow Transplant. 1997;20(7):587–591. doi:10.1038/sj.bmt.1700938.
   PubMed Web of Science ®Google Scholar
• Mohty M, Hubel K, Kroger N, et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49:865–872. doi:10.1038/bmt.2014.39.
   PubMed Web of Science ®Google Scholar
• Goker H, Etgul S, Buyukasik Y. Optimizing mobilization strategies in difficult-to-mobilize patients: the role of plerixafor. Transfus Apher Sci. 2015;53(1):23–29. doi:10.1016/j.transci.2015.05.011.
   Web of Science ®Google Scholar
• Wuchter P, Hubel K. How to find the optimal mobilisation strategy – impact, challenges and solutions. Eur Oncol Haematol. 2016;12(2):87–92. doi:10.17925/EOH.2016.12.02.87.
   Google Scholar
• Zannetti BA, Saraceni F, Cellini C, et al. Low-dose cyclophosphamide versus intermediate-high-dose cyclophosphamide versus granulocyte colony-stimulating factor alone for stem cell mobilization in multiple myeloma in the era of novel agents: a multicenter retrospective analysis. Transplant Cell Ther. 2021;27(3):244.e1–244.e8. doi:10.1016/j.jtct.2020.12.009.
   Google Scholar
• Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol. 2000;18(6):1360–1377. doi:10.1200/JCO.2000.18.6.1360.
   PubMed Web of Science ®Google Scholar
• Partanen A, Turunen A, Valtola J, et al. Mobilization characteristics, blood graft composition, and outcome in diffuse large B-cell lymphoma after autologous stem cell transplantation: results from the prospective multicenter GOA study. Transfusion. 2021;61(2):516–525. doi:10.1111/trf.16198.
   Web of Science ®Google Scholar
• Ataca Atilla P, Bakanay Ozturk SM, Demirer T. How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation? Transfus Apher Sci. 2017;56(2):190–198. doi:10.1016/j.transci.2016.11.005.
   Web of Science ®Google Scholar
• Hopman RK, DiPersio JF. Advances in stem cell mobilization. Blood Rev. 2014;28(1):31–40. doi:10.1016/j.blre.2014.01.001.
   PubMed Web of Science ®Google Scholar
• Pavone V, Gaudio F, Console G, et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant. 2006;37(8):719–724. doi:10.1038/sj.bmt.1705298.
   PubMed Web of Science ®Google Scholar
• Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant. 2008;14(9):1045–1056. doi:10.1016/j.bbmt.2008.07.004.
   PubMed Web of Science ®Google Scholar
• Olivieri A, Marchetti M, Lemoli R, et al. Proposed definition of ‘poor mobilizer’ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo. Bone Marrow Transplant. 2012;47(3):342–351. doi:10.1038/bmt.2011.82.
   PubMed Web of Science ®Google Scholar
• Ings SJ, Balsa C, Leverett D, Mackinnon S, Linch DC, Watts MJ. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol. 2006;134(5):517–525. doi:10.1111/j.1365-2141.2006.06223.x.
   Web of Science ®Google Scholar
• Wang TF, Wen SH, Chen RL, et al. Factors associated with peripheral blood stem cell yield in volunteer donors mobilized with granulocyte colony-stimulating factors: the impact of donor characteristics and procedural settings. Biol Blood Marrow Transplant. 2008;14(11):1305–1311. doi:10.1016/j.bbmt.2008.09.002.
   Web of Science ®Google Scholar
• D’Souza A, Jaiyesimi I, Trainor L, Venuturumili P. Granulocyte colony-stimulating factor administration: adverse events. Transfus Med Rev. 2008;22(4):280–290. doi:10.1016/j.tmrv.2008.05.005.
   PubMedGoogle Scholar
• Becker PS, Wagle M, Matous S, et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant. 1997;3:45–49.
   PubMedGoogle Scholar
• Uy G, Rettig M, Cashen AF. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Expert Opin Biol Ther. 2008;8(11):1797–1804. doi:10.1517/14712598.8.11.1797.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720–5726. doi:10.1182/blood-2008-08-174946.
   PubMed Web of Science ®Google Scholar
• DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27(28):4767–4773. doi:10.1200/JCO.2008.20.7209.
   PubMed Web of Science ®Google Scholar
• Hubel K, Fresen MM, Apperley JF, et al. European data on stem cell mobilization with plerixafor in non-Hodgkin’s lymphoma, Hodgkin’s lymphoma and multiple myeloma patients. A subgroup analysis of the European consortium of stem cell mobilization. Bone Marrow Transplant. 2012;47(8):1046–1050. doi:10.1038/bmt.2011.216.
   Web of Science ®Google Scholar
• Farina L, Spina F, Guidetti A, et al. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating-factor: an algorithm for pre-emptive use of plerixafor. Leuk Lymphoma. 2014;55(2):331–336. doi:10.3109/10428194.2013.802783.
   PubMed Web of Science ®Google Scholar
• Worel N, Fritsch G, Agis H, et al. Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure. J Clin Apher. 2017;32(4):224–234. doi:10.1002/jca.21496.
   Web of Science ®Google Scholar
• Bilgin YM, de Greef GE. Plerixafor for stem cell mobilization: the current status. Curr Opin Hematol. 2016;23(1):67–71. doi:10.1097/MOH.0000000000000200.
   PubMed Web of Science ®Google Scholar
• Giralt S, Costa L, Schriber J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014;20(3):295–308. doi:10.1016/j.bbmt.2013.10.013.
   PubMed Web of Science ®Google Scholar
• Sheppard D, Bredeson C, Huebsch L, Allan D, Tay J. A plerixafor-based strategy allows adequate hematopoietic stem cell collection in poor mobilizers: results from the Canadian Special Access Program. Bone Marrow Transplant. 2014;49(6):751–7555. doi:10.1038/bmt.2014.33.
   PubMed Web of Science ®Google Scholar
• Chabannon C, Bijou F, Miclea JM, Milpied N, Grouin JM, Mohty M. A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the “on-demand” scheme of administration at French autologous hematopoietic stem cell transplant programs. Transfusion. 2015;55(9):2149–2157. doi:10.1111/trf.13141.
   Web of Science ®Google Scholar
• Veeraputhiran M, Jain T, Cronin S, et al. Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant. J Clin Apher. 2014;29(6):293–298. doi:10.1002/jca.21321.
   Web of Science ®Google Scholar
• Yuan S, Nademanee A, Krishnan A, Kogut N, Shayani S, Wang S. Second time a charm? Remobilization of peripheral blood stem cells with plerixafor in patients who previously mobilized poorly despite using plerixafor as a salvage agent. Transfusion. 2013;53(12):3244–3250. doi:10.1111/trf.12198.
   Web of Science ®Google Scholar
• Lanza F, Lemoli RM, Olivieri A, et al. Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. Transfusion. 2014;54(2):331–339. doi:10.1111/trf.12265.
   PubMed Web of Science ®Google Scholar
• Bilgin YM, Visser O, Beckers EA, et al. Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor. Transfusion. 2015;55(5):1021–1027. doi:10.1111/trf.12979.
   Web of Science ®Google Scholar
• Laurent V, Fronteau C, Antier C, et al. Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience. Bone Marrow Transplant. 2021;56(2):395–399. doi:10.1038/s41409-020-01033-8.
   PubMed Web of Science ®Google Scholar
• Hulin C, Offner F, Moreau P, et al. Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab+bortezomib/thalidomide/dexamethasone in the Phase 3 CASSIOPEIA study. Haematologica. 2021. doi:10.3324/haematol.2020.261842.
   Web of Science ®Google Scholar
• Maziarz RT, Nademanee AP, Micallef IN, et al. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells. Biol Blood Marrow Transplant. 2013;19(4):670–675. doi:10.1016/j.bbmt.2013.01.005.
   Web of Science ®Google Scholar
• Lefrere F, Mauge L, Réa D, et al. A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure. Transfusion. 2013;53(3):564–569. doi:10.1111/j.1537-2995.2012.03744.x.
   PubMed Web of Science ®Google Scholar
• Shi PA, Miller LK, Isola LM. Prospective study of mobilization kinetics up to 18 hours after late afternoon dosing of plerixafor. Transfusion. 2014;54(5):1263–1268. doi:10.1111/trf.12459.
   Web of Science ®Google Scholar
• Cid J, Castillo C, Marin P, et al. Increased collection efficiency of CD34+ cells after mobilization with preemptive use of plerixafor followed by leukocytapheresis on the same day. Transfusion. 2020;60(4):779–785. doi:10.1111/trf.15711.
   Web of Science ®Google Scholar
• Yuan S, Nademanee A, Kaniewski M, Palmer J, Shayani S, Wang S. Efficacy of just-in-time plerixafor rescue for Hodgkin’s lymphoma patients with poor peripheral blood stem cell mobilization. Transfusion. 2014;54(3):2015–2021. doi:10.3109/10428194.2012.713480.
   Web of Science ®Google Scholar
• Worel N, Apperley JF, Basak GW, et al. European data on stem cell mobilization with plerixafor in patients with nonhematologic diseases: an analysis of the European consortium of stem cell mobilization. Transfusion. 2012;52(11):2395–2400. doi:10.1111/j.1537-2995.2012.03603.x.
   Web of Science ®Google Scholar
• Bhunia N, Abu-Arja R, Stanek JR, et al. A multicenter report on the safety and efficacy of plerixafor based stem cell mobilization in children with malignant disorders. Transfusion. 2021;61(3):894–902. doi:10.1111/trf.16260.
   Web of Science ®Google Scholar
• Esrick EB, Manis JP, Daley H, et al. Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients. Blood Rev. 2018;2(19):2505–2512. doi:10.1182/bloodadvances.2018016725.
   Web of Science ®Google Scholar
• Shumilov E, Novak U, Jeker B, Taleghani BM, Bacher U, Pabst T. Hematopoietic stem cell mobilization with plerixafor is safe and effective in poorly mobilizing acute myeloid leukemia patients. HemaSphere. 2019;3(2):e176. doi:10.1097/HS9.0000000000000176
   Web of Science ®Google Scholar
• Porrata LF. Autograft immune effector cells and survival in autologous peripheral blood hematopoietic stem cell transplantation. J Clin Apher. 2018;33(3):324–330. doi:10.1002/jca.21611.
   Web of Science ®Google Scholar
• Saraceni F, Shem-Tov N, Olivieri A, Nagler A. Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective. Bone Marrow Transplant. 2015;50(7):886–891. doi:10.1038/bmt.2014.330.
   PubMed Web of Science ®Google Scholar
• Valtola J, Silvennoinen R, Ropponen A, et al. Preemptive plerixafor injection added to pegfilgrastim after chemotherapy in non-Hodgkin lymphoma patients mobilizing poorly. Ann Hematol. 2017;96(11):1897–1906. doi:10.1007/s00277-017-3123-6.
   Web of Science ®Google Scholar
• Turunen A, Partanen A, Valtola J, et al. CD34+cell mobilization, blood graft composition and posttransplant recovery in myeloma patients compared to non-Hodgkin’s lymphoma patients: results of the prospective multicenter GOA study. Transfusion. 2020;60(7):1519–1528. doi:10.1111/trf.15820.
   Web of Science ®Google Scholar
• Valtola J, Silvennoinen R, Ropponen A, et al. Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter study. Leuk Lymphoma. 2019;60(2):453–461. doi:10.1080/10428194.2018.1485911.
   PubMed Web of Science ®Google Scholar
• Micallef IN, Stiff PJ, Nademanee AP, et al. Plerixafor plus granulocyte colony-stimulating factor for patients with non-Hodgkin lymphoma and multiple myeloma: long-term follow-up report. Biol Blood Marrow Transplant. 2018;24(6):1187–1195. doi:10.1016/j.bbmt.2018.01.039.
   PubMed Web of Science ®Google Scholar
• Deol A, Abrams J, Masood A, et al. Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML. Bone Marrow Transplant. 2013;48(8):1112–1116. doi:10.1038/bmt.2013.10.
   Web of Science ®Google Scholar
• Fruehauf S. Current clinical indications for plerixafor. Transfus Med Hemother. 2013;40(4):246–250. doi:10.1159/000354229.
   Web of Science ®Google Scholar
• Milone G, Martino M, Spadaro A, et al. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. Br J Haematol. 2014;164(1):113–123. doi:10.1111/bjh.12606.
   PubMed Web of Science ®Google Scholar
• Hundemer M, Engelhardt M, Bruckner T, et al. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma. J Clin Apher. 2014;29(6):299–304. doi:10.1002/jca.21323.
   Web of Science ®Google Scholar
• Watts NL, Marques MB, Peavey DB, et al. Mobilization of hematopoietic progenitor cells for autologous transplantation using pegfilgrastim and plerixafor: efficacy and cost implications. Biol Blood Marrow Transplant. 2019;25(2):233–238. doi:10.1016/j.bbmt.2018.09.005.
   PubMed Web of Science ®Google Scholar
• Mohty M, Azar N, Chabannon C, et al. Plerixafor in poor mobilizers with non-Hodgkin’s lymphoma: a multi-center time-motion analysis. Bone Marrow Transplant. 2018;53(3):246–254. doi:10.1038/s41409-017-0033-0.
   PubMed Web of Science ®Google Scholar
• Neumann T, Kruger WH, Busermann C, Kiefer T, Dolken G. Successful mobilization of PBSCs in a healthy volunteer donor by addition of plerixafor after failure of mobilization with G-CSF alone. Bone Marrow Transplant. 2011;46(5):762–763. doi:10.1038/bmt.2010.178.
   Web of Science ®Google Scholar
• Schriber J, Fauble V, Sproat LO, Briggs A. Plerixafor ‘just in time’ for stem cell mobilization in a normal donor. Bone Marrow Transplant. 2011;46(7):1026–1027. doi:10.1038/bmt.2010.226.
   Web of Science ®Google Scholar
• Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood. 2008;112(4):990–998. doi:10.1182/blood-2007-12-130179.
   PubMed Web of Science ®Google Scholar
• Hauge AW, Haastrup EK, Sengeløv H, Minulescu L, Dickmeiss E, Fischer-Nielsen A. Addition of plerixafor for CD34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation. Transfusion. 2014;54(4):1055–1058. doi:10.1111/trf.12383.
   PubMed Web of Science ®Google Scholar
• Gattillo S, Marktel S, Rizzo L, et al. Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation. Transfusion. 2015;55(8):1993–2000. doi:10.1111/trf.13059.
   Web of Science ®Google Scholar
• Fiala MA, Park S, Slade M, DiPersio JF, Stockerl-Goldstein KE. Remobilization of hematopoietic stem cells in healthy donors for allogeneic transplantation. Transfusion. 2016;56(9):2331–2335. doi:10.1111/trf.13688.
   Web of Science ®Google Scholar
• Schroeder MA, Rettig MP, Lopez S, et al. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. Blood. 2017;129(19):2680–2692. doi:10.1182/blood-2016-09-739722.
   PubMed Web of Science ®Google Scholar
• Jaiswal SR, Bhakuni P, Joy A, et al. Impact of single-dose plerixafor as an adjunct to granulocyte colony-stimulating factor-based peripheral blood stem cell mobilization on the graft composition and outcome for T cell-replete haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide: a comparative study. Biol Blood Marrow Transplant. 2018;24(3):542–548. doi:10.1016/j.bbmt.2017.11.014.
   PubMed Web of Science ®Google Scholar
• de Greef GE, Braakman E, van der Holt B, et al. The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA-identical sibling donors: results of the HOVON-107 study. Transfusion. 2019;59(1):316–324. doi:10.1111/trf.15037.
   Web of Science ®Google Scholar
• Chen YB, Le-rademacher J, Brazauskas R, et al. Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. Blood Adv. 2019;3(6):875–883. doi:10.1182/bloodadvances.2018027599.
   PubMed Web of Science ®Google Scholar
• Holig K, Schmidt H, Hutter G, et al. Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective Phase II-trial. Bone Marrow Transplant. 2021;56(3):635–645. doi:10.1038/s41409-020-01053-4.
   Web of Science ®Google Scholar
• Cid J, Monsalvo S, Castillo C, et al. Addition of plerixafor to G-CSF in poor mobilizing healthy related donors overcame mobilization failure: an observational case series on behalf of the Grupo Espanol de Trasplante Hematopoyetico (GETH). Transfus Apher Sci. 2021;60(2):103052. doi:10.1016/j.transci.2021.103052.
   Web of Science ®Google Scholar
• Pantin J, Purev E, Tian X, et al. Effect of high-dose plerixafor on CD34+ cell mobilization in healthy stem cell donors: results of a randomized crossover trial. Haematologica. 2017;102(3):600–609. doi:10.3324/haematol.2016.147132.
   PubMed Web of Science ®Google Scholar
• Yeral M, Aytan P, Boga C. Use of plerixafor to mobilize a healthy donor infected with influenza A. Turk J Haematol. 2018;35(2):138–139. doi:10.4274/tjh.2017.0304.
   Web of Science ®Google Scholar
• Couban S, Wong PC, Schultz KR. The case for plerixafor to replace filgrastim as the optimal agent to mobilize peripheral blood donors for allogeneic hematopoietic cell transplantation. Exp Hematol. 2019;70:1–9. doi:10.1016/j.exphem.2018.11.003.
   Web of Science ®Google Scholar
• Green MM, Chao N, Chhabra S, et al. Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. J Hematol Oncol. 2016;9(1):71. doi:10.1186/s13045-016-0301-2.
   Web of Science ®Google Scholar
• Schmitt S, Weinhold N, Dembrowsky K, et al. First results of a phase-II study with the new CXCR4 antagonist POL6326 to mobilize hematopoietic stem cells (HSC) in multiple myeloma (MM). Blood. 2010;116:824. doi:10.1182/blood.V116.21.824.824
   Web of Science ®Google Scholar
• Abraham M, Biyder K, Begin M, et al. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells. 2007;25(9):2158–2166. doi:10.1634/stemcells.2007-0161.
   PubMed Web of Science ®Google Scholar
• Domingues MJ, Nilsson SK, Cao B. New agents in HSC mobilization. Int J Hematol. 2017;105(2):141–152. doi:10.1007/s12185-016-2156-2.
   PubMed Web of Science ®Google Scholar